 WATERTOWN, Mass.--BUSINESS WIRE--SQZ Biotechnologies NYSE: SQZ, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported second quarter 2021 financial results and recent portfolio updates. This was an exciting quarter for the company as we reported first-in-human data at ASCO for our investigational APC cell therapy, which demonstrated an encouraging safety profile, rapid SQZ manufacturing and early signs of immune activity, said Armon Share 